Septerna, Inc. (SEPN)

Over the past six months, Septerna's stock has experienced several notable events and fluctuations. Analyst sentiment has been largely positive, with multiple firms upgrading or initiating coverage with buy ratings and raising price targets. Septerna shares surged in early December 2025, reaching an all-time high, and also saw gains in mid-January 2026, outperforming broader biotech peers. There were also periods of decline, such as a 7% drop in late January 2026, and a 2.39% decline in early February 2026. In January 2026, Septerna appointed Mark A. Wilson as Chief Legal Officer, and highlighted advancements in GPCR drug discovery at the J.P. Morgan Healthcare Conference. Despite a recent earnings miss and negative margins, analyst sentiment has remained constructive, and the company reported a strong cash position of $420.8 million, expected to fund operations into early 2028.

There is no explicit information indicating demand seasonality for Septerna, Inc.'s products or services. Demand for its future products would likely be driven by factors such as disease prevalence, unmet medical needs, and the efficacy and safety profile of its treatments, rather than seasonal fluctuations.

Septerna, Inc. is a clinical-stage biotechnology company in South San Francisco, California, specializing in oral small molecule therapies. Operating in the Healthcare sector, specifically Biotechnology, Septerna uses its Native Complex Platform™ to target G protein-coupled receptors (GPCRs). The company's pipeline focuses on endocrinology, immunology and inflammation, and metabolic diseases. Key product candidates include SEP-786 for hypoparathyroidism, SEP-631 for chronic spontaneous urticaria and other mast cell diseases, and TSHR programs for Graves' disease and thyroid eye disease. Septerna is also developing oral small molecule single- and multi-incretin receptor agonists for metabolic disorders and SEP-479 as a next-generation oral PTH1R agonist development candidate.

Septerna, Inc. is headquartered in South San Francisco, California, United States. Its primary operations are focused on research and development, with its market reach currently centered on advancing its drug pipeline.

Septerna's brand reputation over the past year appears to be largely positive, particularly within the investment and biotechnology communities. The company has consistently received a "Moderate Buy" consensus rating from analysts, with several firms initiating or upgrading coverage. A significant $2.2 billion collaboration with Novo Nordisk has positively positioned the company. Septerna's stock has outperformed both the US Pharmaceuticals industry and the broader US Market. The appointment of Mark A. Wilson as Chief Legal Officer in January 2026 was seen as a positive move. Ongoing clinical development momentum for its pipeline candidates has been met with positive investor response. While the company experienced a recent earnings miss and negative margins, analyst sentiment has remained constructive.

Septerna, Inc. has a significant number of institutional owners, with 164 institutional owners and shareholders holding a total of 46,627,607 shares. Key institutional shareholders include Ra Capital Management, L.P., TRV GP V, LLC, Driehaus Capital Management LLC, TRV GP VI, LLC, BVF Inc/il, Samsara BioCapital, LLC, Siren, L.L.C., Vanguard Group Inc, BlackRock, Inc., and Goldman Sachs Group Inc. Notable individual owners and insiders include Jeffrey T. Finer (CEO and President), Uwe Klein (SVP, Biological Sciences), Elizabeth P. Bhatt (President and COO), Daniel D. Long (SVP, Drug Discovery), Jae B. Kim (Chief Medical Officer), Gil M. Labrucherie (Chief Financial Officer), and Alan Ezekowitz (Director). Insider transactions include a sale by Daniel D. Long in November 2025, contrasting with earlier buy transactions by Alan Ezekowitz, Gil M. Labrucherie, and Jeffrey Finer, as well as significant purchases by Third Rock Ventures VI, L.P.